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which is not constrained to the epicardial coronary venous anatomy, may provide superior hemodynamics (10) (11) (12) and improved CRT response, which may be of particular benefit in ischemic patients and nonresponders to conventional CRT (12) (13) (14) . The site of optimal LVendo stimulation is highly variable in ischemic and nonischemic groups (15) with no reliable method to guide optimal LVendo lead placement. Cardiac magnetic resonance (CMR) could potentially identify the target for LV lead placement, being able to delineate scar and dyssynchrony (7) . Endocardial contact mapping can demonstrate exquisite detail of endocardial activation as well as location and size of myocardial scar. Because patients with ischemic cardiomyopathy and myocardial scar have the poorest response to CRT and the most to gain from LVendo pacing, advanced imaging and mapping modalities may be able to guide the optimal site for endocardial LV lead delivery.
We hypothesized that in a group of ischemic patients (with demonstrable myocardial scar on CMR) and a high prevalence of CRT nonresponse, LVendo pacing would produce a superior hemodynamic response compared with the optimal epicardial response (LVepi). Furthermore, by pacing multiple sites, we sought to investigate whether the optimal site of LV stimulation (both epicardially and endocardially) could be predicted on the basis of scar and/or the latest point of electrical activation. By comparing endocardial contact mapping data with CMR, we further sought to elucidate the mechanisms of improved response with LVendo pacing and whether these imaging modalities could be used to guide the optimal LVendo pacing sites.
METHODS
The study complied with the Declaration of Helsinki and the protocol was approved by the local ethics committee. Informed consent was obtained from each patient. Patients with ischemic cardiomyopathy (judged by significant coronary artery disease and myocardial fibrosis on CMR), QRS duration of <150 ms, and previously implanted CRT (mean duration of implant 26 AE 21 months) have a phenotype of suboptimal response to CRT and were intentionally selected for study (3) Points with a sensed bipolar electrogram amplitude of <0.5 mV were defined as scar and colored grey, points >1.5 mV were defined as representing healthy tissue and colored purple and those points in between defined as border zone with a color range (16) .
Temporary placement of a high right atrial quadripolar catheter was used for atrial sensing. Initially, the optimal epicardial site with atrial synchronous biventricular pacing was assessed using the patient's chronically implanted LV lead (LVepi1) and a second, temporary epicardial LV lead placed via the femoral vein (LVepi2) to allow multiple epicardial pacing sites from different veins and along the same vein ( Figure 1 ). The optimal endocardial site was then assessed using the roving LV endocardial decapolar catheter. The LV was divided into 12 locations (anterior, lateral, inferior, septal at basal, mid and apical levels) and randomized (Microsoft Excel). We plan- 
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STATISTICAL METHODS. Continuous variables with a Gaussian distribution were described using mean AE SD. Values are mean AE SD.
LVendo ¼ endocardial pacing; LVepi ¼ epicardial pacing; other abbreviations as in Tables 1 and 2 . Mixed effect model for all data points achieving capture comparing epicardial and endocardial pacing across the dependent variables as shown. A total of 32 epicardial and 87 endocardial data points were compared across 8 patients.
AHR ¼ acute hemodynamic response; QLV ¼ first ventricular depolarization (earliest onset QRS duration on surface 12 lead electrocardiogram) to the nadir signal on the LV lead electrogram. There was a nonsignificant trend toward an improved AHR with basal compared with mid and apical positions at all sites (LVepi and LVendo) (base 13.7 AE 11, mid 8.1 AE 9.8, apex 9.6 AE 12.7; p ¼ 0.07).
OPTIMAL LV SITE LOCATION. Epicardial stimulation sites were limited according to the coronary venous anatomy and the best achievable epicardial pacing locations were therefore confined to the AHA segments subtended by these veins. In 7 of 8 patients, the optimal LVepi pacing site was inferolateral/ inferior; in the other patient the basal anterior site was best in keeping with the belief that pacing from the inferolateral/inferior wall is the optimal site of epicardial stimulation in the majority of subjects.
LVendo pacing was not limited to the distribution of the coronary veins and there was substantial individual variation in the optimal site producing the best AHR ( Figure 3) . Behar et al. Table 1 ).
DISCUSSION
We studied the optimal site for both LVepi and LVendo stimulation in a cohort of patients with ischemic heart disease with poor response to conventional CRT. The principal findings were as follows.
1. Indiscriminate endocardial pacing was superior to epicardial stimulation, associated with a similar first ventricular depolarization, shortened stimulation-QRS duration and shortened paced QRS duration.
Optimal achievable endocardial AHR was superior
to the optimal achievable epicardial AHR. 
COMPARISON WITH PREVIOUS STUDIES.
In keeping with the current study, LVendo pacing has been found to be superior to conventional CRT in both ischemic and nonischemic patients (11-13). Derval et al. (22) found that LVendo pacing was superior to posterolateral LVepi pacing in nonischemic patients with significant individual variation between the optimal LVendo pacing sites (22) . Spragg et al. (10) undertook EAM and AHR measurement in 11 patients with ischemic heart disease and dyssynchronous heart failure at the time of ventricular tachycardia ablation and found LVendo was superior to LVepi pacing (10) . Our group has shown the superiority of LVendo pacing over conventional CRT in a group of ischemic and nonischemic patients (11) . The superiority of LVendo pacing over LVepi seems to be reproducible, but with a significant variability in the optimal site between patients in all the aforementioned studies (10) (11) (12) .
The current study has some important differences A notable finding of the current study was the superiority of LVendo over LVepi at the same site.
Previous studies have suggested no difference in ischemic and nonischemic patients, however we found a significant benefit with endocardial pacing (15.2 AE 10.7% vs. 7.6 AE 6.3%; p ¼ 0.014). Spragg et al.
(10) compared LVendo and LVepi at the same site in 7 patients and found LVendo pacing increased dP/dt max by 36% from baseline compared with 29% via LVepi although this increase was not statistically significant. These differences may be related to the different population studied, but also that we assessed and optimized LVepi pacing in both the anterior and posterolateral regions. Our data are in keeping with both animal studies (13) and a computer modelling study from our group (14) . Finally, our patients had CMR data that could be correlated with
Optimal, Endocardial LV Delivered CRT the results of EAM, which was not the case in the aforementioned studies (Figure 4) . In keeping with this finding, the Q-LV at the optimal LVendo sites were not significantly longer than those at the optimal LVepi site. It seems likely that, on the basis of our and other prior findings, the latest activating site is not necessarily the optimal site to pace with respect to improved hemodynamics. This may be due to localized areas of slow conduction with islands of viable tissue within areas of scar that activate late (and therefore have a long Q-LV). Likewise, when stimulation is performed at that site, impulse propagation is also slow out of this area and does not result in effective resynchronization. An example of this is seen in Figure 5 in a patient with a large circumferential midventricular and apical infarct with areas of late activating tissue within the scar. It is possible that seeking a late activated site may be beneficial, but only if conduction out of that site is not also delayed or blocked by regions of scar. This is analogous to a Goldilocks effect where the optimal site in ischemic patients because of scar/slow conduction may be not too early, not too late but just right, somewhere in between the two. Dilated, globular heart with a heavy burden of myocardial scar. Earliest activation is white and latest activation blue/purple. In this case, LVendo locations were not superior to conventional LVepi with respect to the AHR. The point of latest electrical activation in this case is around the anteroseptum, most likely as a result of slow activation spreading and encircling a large region of scar. Although these sites are the latest activated they will not produce a good AHR because they are in scar and may explain why the latest activated site is not always the optimal pacing site. Abbreviations as in Figures 1 and 3 . (Table 2) , an even greater AHR was achievable when both epicardial and endocardial sites were optimized. Therefore, an image-guided, targeted approach could be a strategy for identifying the optimal location for LV lead stimulation. CMR techniques do, however, require further evaluation to assess their merit in guiding endocardial pacing sites and techniques which allow CMR derived scar and mechanical activation to be fused onto live fluoroscopy for epicardial LV lead guidance may also be used for LVendo lead guidance (18, 25) . 
CONCLUSIONS
Our findings suggest that, in ischemic patients with poor CRT response, endocardial pacing is superior to epicardial pacing with an even greater response achievable with optimization for each set of protocols. The mechanism of benefit may be due to the ability to access more optimal sites that cannot be reached by the constraints of the CS anatomy.
Furthermore, guidance to the optimal LV pacing site may be aided by modalities such as CMR to target nonscarred and delayed activating sites. 
